Subgroups according to BASDAI/ASDAS category (baseline)

Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study - Roberta Ramonda, Mariagrazia Lorenzin, Maria Sole Chimenti, Salvatore D'Angelo, Antonio Marchesoni, Carlo Salvarani, Ennio Lubrano

Disease control in patients with ankylosing spondylitis in real clinical practice in Spain: Results of the MIDAS study

JCM, Free Full-Text

Full article: POSTER PRESENTATIONS

WO2021067465A1 - Treating spondyloarthritic and psoriatic conditions with upadacitinib - Google Patents

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial - The Lancet

POS0235 COMPARISON OF AXIAL AND PERIPHERAL MANIFESTATIONS IN PATIENTS WITH PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS IN UPADACITINIB CLINICAL TRIALS

Delayed treatment with a tumor necrosis factor alpha blocker associated with worse outcomes in patients with spondyloarthritis: data from the Czech National Registry ATTRA - Tomas Milota, Jana Hurnakova, Karel Pavelka, Zlatuse

Frontiers The BASDAI Cut-Off for Disease Activity Corresponding to the ASDAS Scores in a Taiwanese Cohort of Ankylosing Spondylitis

ASDAS-CRP (full analysis set). (A) Change in ASDAS-CRP score from

Monitoring of Disease Activity With a Smartphone App in Routine Clinical Care in Patients With Axial Spondyloarthritis

Comparison of (A) ASDAS vs SASDAS in their capacity to each

Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab

Frontiers Correlation Between Chronic Pain Acceptance and Clinical Variables in Ankylosing Spondylitis and Its Prediction Role for Biologics Treatment